10-Q: SIGA Technologies Q2 2026 Revenue Drops Amidst Shifting Contract Landscape

SIGA Technologies reports a substantial year-over-year decline in revenue and net income for the second quarter of 2026, primarily driven by lower product sales compared to the prior year's strong performance.

Summary

• SIGA Technologies reported total revenues of $41.0 million for the three months ended June 30, 2026, a decrease from $81.1 million in the same period of 2025.
• Net income for the three months ended June 30, 2026, was $12.5 million, down from $35.5 million in the prior year's quarter.
• For the six months ended June 30, 2026, total revenues were $47.2 million, compared to $88.2 million for the same period in 2025.
• Net income for the six months ended June 30, 2026, was $9.0 million, a significant decrease from $35.1 million in the prior year.
• The company's cash and cash equivalents stood at $117.6 million as of June 30, 2026.
• The 19C BARDA Contract remains a significant revenue driver, with $24.4 million in IV TPOXX sales in Q2 2026 and $41.4 million in product sales for the six months.
• International sales contributed $13.0 million in Q2 2026 and $13.0 million for the six months ended June 30, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to a significant decrease in revenue and net income compared to the prior year period, despite ongoing government contracts.

Positives

• Maintained a strong cash position with $117.6 million in cash and cash equivalents as of June 30, 2026.
• Continued to generate revenue from the significant 19C BARDA Contract, including $24.4 million in IV TPOXX sales in Q2 2026.
• Secured $13.0 million in international sales during the second quarter of 2026.
• The company's disclosure controls and procedures were deemed effective as of June 30, 2026.
• The European Medicines Agency (EMA) confirmed the positive benefit-risk balance of Tecovirimat-SIGA for smallpox, cowpox, and vaccinia complications.

Negatives

• Total revenues for Q2 2026 decreased by approximately 49.5% to $41.0 million from $81.1 million in Q2 2025.
• Net income for Q2 2026 decreased by approximately 64.9% to $12.5 million from $35.5 million in Q2 2025.
• Total revenues for the six months ended June 30, 2026, decreased by approximately 46.4% to $47.2 million from $88.2 million in the prior year.
• Net income for the six months ended June 30, 2026, decreased by approximately 74.3% to $9.0 million from $35.1 million in the prior year.
• Product sales and supportive services revenue in Q2 2026 were $37.9 million, down from $79.1 million in Q2 2025.
• The company's effective tax rate decreased to 16.1% in Q2 2026 from 24.9% in Q2 2025, partly due to forecasted full-year losses.
• The EMA recommended that Tecovirimat-SIGA no longer be used for the treatment of mpox, impacting potential future indications.

Risks

• The nascent international biodefense market may not develop sufficiently for continued international success.
• Potential products, including alternative uses or formulations of TPOXX, may not prove efficacious or safe in further trials.
• Delays in product deliveries or revenue recognition could occur due to actions of contract manufacturing organizations or other vendors.
• Obtaining or maintaining necessary governmental approvals for products or new uses could be challenging.
• Challenges to SIGA's patent and other property rights could adversely affect the business.
• Regulatory requirements may necessitate further testing, delaying or preventing market approvals.
• The volatile and competitive biotechnology industry could hinder product development and marketing efforts.
• Changes in domestic or foreign economic and market conditions may impact research advancement or product performance.

Future Outlook

The company believes its liquidity and capital resources are sufficient for at least the next twelve months. The company is targeting a Supplemental NDA submission to the FDA for a smallpox PEP indication in the first half of 2027, based on ongoing sample analyses from an immunogenicity trial. The company's forecast for full-year losses is based on orders received to date and is subject to updates.

Management Comments

• Management has evaluated the effectiveness of the company's disclosure controls and procedures as of June 30, 2026, and concluded they were effective.
• Management has disclosed to auditors and the audit committee all significant deficiencies and material weaknesses in internal control over financial reporting, and any fraud involving management or employees with a significant role in internal control.
• Management believes that the resolution of current pending legal matters, if any, will not have a material adverse effect on the business, consolidated financial position, results of operations, or cash flow.

Industry Context

StockSavvy.ai notes that SIGA Technologies operates in the niche biodefense and antiviral market. The significant year-over-year revenue decline suggests a normalization after a period of potentially higher demand or contract fulfillment, and highlights the company's reliance on large government contracts like the BARDA contract. The mpox regulatory setback in Europe also presents a challenge for potential label expansions.

Comparison to Industry Standards

• The revenue decline of approximately 49.5% in Q2 2026 compared to Q2 2025 is a significant drop, indicating a potential shift in demand or contract cycles compared to the prior year's performance.
• The decrease in operating income from $45.7 million in Q2 2025 to $13.9 million in Q2 2026 suggests a substantial reduction in profitability from core operations.
• The effective tax rate of 16.1% in Q2 2026, compared to 24.9% in Q2 2025, reflects changes in profitability and tax planning, including the impact of forecasted losses.
• The company's cash position remains robust at $117.6 million, which is generally a positive indicator for financial stability within the pharmaceutical sector, though the decrease from $155.0 million warrants monitoring.

Legal Proceedings

• From time to time, the company may be involved in various claims, suits, investigations, and proceedings, including collections claims, breach of contract claims, labor and employment claims, and tax matters.
• Management believes the resolution of current pending matters will not have a material adverse effect on the business, financial position, results of operations, or cash flow.

Related Party Transactions

• The company has a ten-year Office Lease agreement with MacAndrews & Forbes Incorporated (M&F) for its corporate headquarters in New York, New York, with monthly rent and facility fees.

Stakeholder Impact

• Shareholders may be impacted by the significant decrease in revenue and net income compared to the prior year.
• The company's robust cash position provides some security for ongoing operations and potential future investments.
• Government agencies (customers) are continuing to procure TPOXX under existing contracts, indicating ongoing demand for the product.
• Suppliers and contract manufacturers are integral to the supply chain, and their performance can impact delivery timelines and costs.

Next Steps

• Targeting a Supplemental NDA submission to the FDA for a smallpox PEP indication in the first half of 2027.
• Continue to monitor evolving tariff policies and their potential impact on product and operating costs.
• Update full-year loss forecasts based on new procurement orders.

Key Dates

Recommendation

The significant year-over-year decline in revenue and net income, coupled with the setback in European mpox indications, warrants a cautious approach. While the company maintains a strong cash position and continues to service government contracts, the uncertainty surrounding future demand and the lack of new growth drivers suggest a 'hold' rating until clearer signs of recovery or new market opportunities emerge.

Keywords

TPOXX, tecovirimat, smallpox, antiviral, BARDA, government contracts, pharmaceutical, biodefense